Review
Oncology
Florent Petitprez, Mira Ayadi, Aurelien de Reynies, Wolf H. Fridman, Catherine Sautes-Fridman, Sylvie Job
Summary: The number of prognostic markers for ccRCC has been increasing over the last 15 years, but they have not been integrated and compared. 20% of these markers are involved in four biological pathways altered in ccRCC, but the main genes in ccRCC carcinogenesis are not the most relevant for assessing survival.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Summary: Biological discoveries in the past two decades have revolutionized the treatment of renal cell carcinoma. The development of agents targeting pro-angiogenic pathways and immunogenicity have significantly impacted the management of clear cell renal cell carcinoma. Clear cell is the most common subtype, and therapies have focused on the Von Hippel Lindau gene alterations, leading to the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors. Combinations of these treatments have become the standard of care for advanced clear cell renal cell carcinoma, with promising new therapeutic targets under development.
Article
Oncology
Elisa Meacci, Dania Nachira, Edoardo Zanfrini, Jessica Evangelista, Elizabeth Katherine Anna Triumbari, Maria Teresa Congedo, Leonardo Petracca Ciavarella, Marco Chiappetta, Maria Letizia Vita, Giovanni Schinzari, Ernesto Rossi, Giampaolo Tortora, Marco Lucchi, Marcello Ambrogi, Fabrizia Calabro, Francesco Petrella, Lorenzo Spaggiari, Marco Mammana, Andrea Lloret Madrid, Federico Rea, Diomira Tabacco, Stefano Margaritora
Summary: Pulmonary metastasectomy plays a significant role in the long-term survival and disease-free survival of patients with metastatic renal cell carcinoma, benefiting those with specific prognostic factors. By evaluating factors affecting survival, disease-free interval, and disease-free survival, clinicians can identify patients who are likely to benefit from pulmonary metastasectomy.
Review
Oncology
Kalle E. Mattila, Paula Vainio, Panu M. Jaakkola
Summary: Approximately one fifth of newly diagnosed renal cell carcinoma patients have metastatic disease, and over one third of localized patients will develop distant metastases after surgery. Tumor size, grade, and extension into blood vessels are valid factors for predicting disease recurrence after surgery. Ongoing adjuvant therapy trials may reveal prognostic features for high-risk patients.
Article
Oncology
Yue Wang, Xi Tian, Shu-Xuan Zhu, Wen-Hao Xu, Aihetaimujiang Anwaier, Jia-Qi Su, Hua-Lei Gan, Yuan-Yuan Qu, Jian-Yuan Zhao, Hai-Liang Zhang, Ding-Wei Ye
Summary: This study identified TPX2 as a potential prognostic and therapeutic biomarker in PRCC2. PRCC2 has worse overall survival and distinct molecular characteristics compared to PRCC1. Higher expression of TPX2 was associated with worse overall survival and elevated kinesin family gene expression in high-risk PRCC2. Abundance of tumor infiltrating M1 macrophage was significantly higher in PRCC2 and correlated with worse overall survival. mTOR inhibitors may have good efficacy in high-risk PRCC2 patients.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Cell Biology
Gu Yue, Li Deyu, Tao Lianyuan, Shao Fengmin, Gao Mei, Huang Yajun, Zhang Wenwen, Yan Lei
Summary: The study revealed that age is an independent prognostic factor for clinicopathological characteristics and survival of mRCC patients. Significant differences were observed between older and younger patients in various aspects, such as marital status, race, sex, year of diagnosis, histology grade, tumor size, treatment type, and metastasis pattern. Older patients with mRCC showed different natural metastasis patterns and poorer overall survival compared to younger patients.
Article
Cell Biology
Yue Wu, Xi Zhang, Xian Wei, Huan Feng, Bintao Hu, Zhiyao Deng, Bo Liu, Yang Luan, Yajun Ruan, Xiaming Liu, Zhuo Liu, Jihong Liu, Tao Wang
Summary: By analyzing differentially expressed ubiquitin-related genes in ccRCC, seven prognostic-related genes were identified and used to construct a predictive signature, which showed good prediction accuracy for evaluating tumor progression in ccRCC patients. The signature was confirmed to be an independent prognostic factor related to the prognosis of ccRCC patients, potentially providing diagnostic and prognostic markers for ccRCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Chaston Weaver, Khaled Bin Satter, Katherine P. Richardson, Lynn K. H. Tran, Paul M. H. Tran, Sharad Purohit
Summary: This review focuses on the molecular changes associated with the development of clear cell renal carcinoma (ccRCC) and the gene expression and protein signatures, highlighting the importance of utilizing these molecular profiles in clinical practice. Machine learning and precision medicine may help overcome the barriers in incorporating tumor molecular profiles into the diagnosis and treatment of ccRCC.
Article
Oncology
Fiorella L. Roldan, Laura Izquierdo, Mercedes Ingelmo-Torres, Juan Jose Lozano, Raquel Carrasco, Alexandra Cunado, Oscar Reig, Lourdes Mengual, Antonio Alcaraz
Summary: In this study, molecular markers for disease progression in ccRCC were identified and a gene expression-based signature was developed. This signature enhances the prediction of prognosis and could be used for personalized disease management.
Article
Cell Biology
Wenhao Xu, Aihetaimujiang Anwaier, Chunguang Ma, Wangrui Liu, Xi Tian, Jiaqi Su, Wenkai Zhu, Guohai Shi, Shiyin Wei, Hong Xu, Yuanyuan Qu, Dingwei Ye, Hailiang Zhang
Summary: This study identified immunophenotyping clusters in ccRCC that can improve prognostic accuracy of the immune contexture in the tumor microenvironment. The study discovered novel independent prognostic indicators in ccRCC, highlighting the relationship between tumor phenotype and immune microenvironment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Mathieu Larroquette, Felix Lefort, Luc Heraudet, Jean-Christophe Bernhard, Alain Ravaud, Charlotte Domblides, Marine Gross-Goupil
Summary: This article summarizes the main discoveries made in the treatment of metastatic clear cell renal cell carcinoma in recent years, including different generations of anti-VEGF targeted therapy drugs and immune checkpoint inhibitors (ICI), and provides an overview of the future developments in this field. The article also discusses new treatment approaches, such as escalation/de-escalation strategies, and introduces some potential new treatments to further improve patient survival.
Editorial Material
Oncology
Elizabeth P. Henske, Liang Cheng, A. Ari Hakimi, Toni K. Choueiri, David A. Braun
Summary: Chromophobe renal cell carcinoma (ChRCC) is the second most common variant of non-clear cell renal cell carcinoma. ChRCC differs from clear cell RCC (ccRCC) in terms of genetics, genomics, metabolism, cell of origin, and response to targeted and immune therapies. The pathogenesis of ChRCC is not well understood, but current evidence suggests two potential mechanisms: mTORC1 hyperactivation through PTEN pathway mutations and mitochondrial dysfunction leading to oxidative stress.
Article
Multidisciplinary Sciences
Qian Long, Chunyu Huang, Jinsheng Huang, Qi Meng, Yanjun Cheng, Yilin Li, Liru He, Miao Chen, Changlin Zhang, Xiaonan Wang, Wancui Zhu, Jin Peng, Dingbo Shi, Fufu Zheng, Pei Dong, Wuguo Deng
Summary: This study investigates the biological and clinical significance of JAK3 promoter methylation in clear cell renal cell carcinoma (ccRCC). The results show that JAK3 promoter is significantly hypomethylated in ccRCC tumor tissues and is strongly correlated with high JAK3 mRNA expression. JAK3 promoter hypomethylation predicts advanced clinicopathological characteristics and shorter overall survival. Furthermore, JAK3 promoter methylation is associated with immune cell infiltration and expression of immune checkpoint molecules. The findings suggest that JAK3 promoter methylation may serve as a molecular biomarker for predicting responses to immune checkpoint inhibitors in ccRCC.
JOURNAL OF ADVANCED RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Zuhu Yu, Chong Lu, Bin Lu, Hong Gao, Rongfang Liang, Wuxing Xiang
Summary: This study identified necroptosis-related microRNAs (miRNAs) associated with the prognosis of clear cell renal cell carcinoma (ccRCC), and developed a prognostic signature to predict overall survival in ccRCC patients. The targeted genes of these miRNAs were predicted using miRNA databases, and their functional and pathway associations with ccRCC prognosis were investigated. The differential expression of the three miRNAs in the signature was validated in ccRCC tissues.
Article
Immunology
Yankuo Liu, Zhiyuan Shi, Jianzhong Zheng, Zeyuan Zheng, Huimin Sun, Zuodong Xuan, Yang Bai, Meiling Fu, Yifan Du, Chen Shao
Summary: Through the study of clear cell renal cell carcinoma (ccRCC) patients, ANOIKIS-related genes (ARGs) were found to be closely associated with ccRCC prognosis. The prognostic model constructed using these ARGs can effectively predict ccRCC prognosis, and these ARGs are closely related to the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Transplantation
Kerem Can Yilmaz, Orcun Ciftci, Arzu Neslihan Akgun, Haldun Muderrisoglu, Sedat Boyacioglu, Asuman Nihan Haberal, Gokhan Moray, Mehmet Haberal
EXPERIMENTAL AND CLINICAL TRANSPLANTATION
(2020)
Article
Obstetrics & Gynecology
Damla Gurkan, Aylin Ceren Akin, Hanifi Sahin, Yusuf Aytac Tohma, Eda Adeviye Sahin, Emre Gunakan, Nidal Iflazoglu, Asuman Nihan Haberal, Ali Ayhan
JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2020)
Article
Obstetrics & Gynecology
Aycag Yorganci, Mehmet Mutlu Meydanli, Nezaket Kadioglu, Salih Taskin, Fulya Kayikcioglu, Duygu Altin, Latife Atasoy, Asuman Nihan Haberal, Tugba Kinay, Mehmet Akif Akgul, Omer Lutfi Tapisiz, Ozlem Evliyaoglu, Ozlem Moraloglu Tekin, U. Firat Ortac, Ali Ayhan
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION
(2020)
Article
Medicine, General & Internal
Yalcin Kizilkan, Yusuf Aytac Tohma, Samet Senel, Emre Gunakan, Ahmet Ibrahim Oguzulgen, Binhan Kagan Aktas, Suleyman Bulut, Cevdet Serkan Gokkaya, Cuneyt Ozden, Hakan Ozkardes, Ali Ayhan
Article
Urology & Nephrology
Ediz Vuruskan, Hakan Ercil, Umut Unal, Ergun Alma, Hakan Anil, Hilmi Erdem Sumbul, Mehmet Eflatun Deniz, Mehmet Resit Goren
Summary: The study identified predictive factors affecting the success of treatment with nephrectomy in patients with poorly functioning kidney and nephrogenic hypertension, including preoperative hypertension duration, advanced age, and presence of metabolic syndrome.
UROLOGIA INTERNATIONALIS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gurcan Erbay, Mehmet Resit Goren, Elif Karadeli, Burcak Pekoz, Zafer Koc, Sami Arica
Summary: Histogram analysis of apparent diffusion coefficient (ADC) values can help differentiate oncocytomas from malignant renal neoplasms (MRNs) to a certain extent. Different types of renal tumors show significant differences in ADC values, which may have important implications for tumor diagnosis and classification.
IRANIAN JOURNAL OF RADIOLOGY
(2021)
Letter
Pediatrics
Mehmet Resit Goren, Erman Ceyhan, Cevahir Ozer, Ferhat Kilinc, Hakan Ozkardes
JOURNAL OF PEDIATRIC UROLOGY
(2023)
Article
Pediatrics
Mehmet Resit Goren, Erman Ceyhan, Cevahir Ozer, Ferhat Kilinc, Hakan Ozkardes
Summary: This study investigated the impact of detrusor pressure on renal scarring in children with sterile vesicoureteral reflux (VUR). The results showed that children with detrusor pressure over 26 cm/H2O were more likely to develop renal scarring.
JOURNAL OF PEDIATRIC UROLOGY
(2023)
Article
Oncology
Bermal Hasbay, Mehmet Resit Goren, Mehmet Vehbi Kayra
Summary: This study compared the age, gender, survival, and etiology of patients diagnosed with urothelial carcinoma (UC) in different localizations of the genitourinary system. The study included 64 patients diagnosed with concurrent or subsequent lower and/or upper tract UC. The results showed that UC can affect multiple organs, and close surveillance of patients diagnosed with UC in the upper or lower urinary tract who are smokers is recommended to prevent the formation of primary tumors in other regions.
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
(2023)
Meeting Abstract
Immunology
B. Handan Ozdemir, Gonca Ozgun, Ebru H. Ayvazoglu Soy, Nihan Haberal, Mehmet A. Haberal
Meeting Abstract
Immunology
B. Handan Ozdemir, Gonca Ozgun, Aysegul Yucel Polat, Nihan Haberal, Gokhan Moray, Mehmet A. Haberal
Meeting Abstract
Surgery
B. H. Ozdemir, G. Ozgun, E. H. Ayvazoglu Soy, N. Haberal, M. Haberal
AMERICAN JOURNAL OF TRANSPLANTATION
(2020)
Meeting Abstract
Surgery
H. B. Ozdemir, G. Ozgun, A. Yucel Polat, N. Haberal, G. Moray, M. Haberal
AMERICAN JOURNAL OF TRANSPLANTATION
(2020)
Article
Obstetrics & Gynecology
Irem Alyazici Kucukyildiz, Emre Gunakan, Huseyin Akilli, Asuman Nihan Haberal, Esra Kuscu, Ali Haberal, Ali Ayhan
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY
(2020)
Article
Obstetrics & Gynecology
Huseyin Akilli, Yusuf Aytac Tohma, Emre Gunakan, Irem Kucukyildiz, Mehmet Tunc, Nihan Reyhan Haberal, Ali Ayhan
Summary: This study aimed to evaluate the factors affecting parametrial involvement in cervical cancer patients with tumor size <= 4 cm and select the low-risk patient group based on long-term oncologic outcomes. The results showed that LVSI and DSI were significant factors increasing the risk of parametrial involvement, while smaller tumor size was associated with lower risk.
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION
(2021)